Cantor Fitzgerald Reiterates Overweight on Biogen, Maintains $311 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Biogen (NASDAQ:BIIB) and maintained a price target of $311.
December 20, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Eric Schmidt reaffirmed an Overweight rating on Biogen, with a price target of $311, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests a positive sentiment towards Biogen's stock. The maintained price target of $311 implies a potential upside from the current trading price, which could positively influence investor confidence and the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100